1. Age ≥ 18 years 
2. Patient with breast cancer, histologically proven, metastatic or locally advanced 
3. Patient treated by Eribulin between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part). 
4. Patient with at least an assessment of the response to Eribulin 

NCT02393287_inc_T5
Person
Age
NCT02393287_inc_T6
Value
≥ 18 years
NCT02393287_inc_T7
Condition
breast cancer
NCT02393287_inc_T8
Procedure
histologically
NCT02393287_inc_T9
Value
proven
NCT02393287_inc_T10
Qualifier
metastatic
NCT02393287_inc_T11
Qualifier
locally advanced
NCT02393287_inc_T12
Scope
histologically proven, metastatic or locally advanced
NCT02393287_inc_T13
Drug
Eribulin
NCT02393287_inc_T14
Temporal
between January and October 2014
NCT02393287_inc_T15
Temporal
between November 2014 and September 2015
NCT02393287_inc_T16
Scope
between January and October 2014 (for the retrospective part) or between November 2014 and September 2015 (for the prospective part)
NCT02393287_inc_T17
Drug
Eribulin
NCT02393287_inc_T18
Procedure
assessment of the response